Methylene Blue Studies

A Drug With Over 100 Years of Clinical Use

Methylene blue was first synthesized in 1876 by the German chemist Heinrich Caro. Within two decades, physicians were using it as a treatment for malaria, making it one of the earliest synthetic drugs ever used in medicine. That history of clinical use spans more than a century and continues today.

In 2016, the U.S. Food and Drug Administration approved methylene blue as a prescription drug under the brand name Provayblue. The approved indication is methemoglobinemia, a blood condition in which hemoglobin (the protein in red blood cells that carries oxygen) loses the ability to hold oxygen properly, preventing the blood from delivering enough oxygen to the body. The drug is given intravenously in clinical settings to reverse this condition. You can read the FDA's Provayblue approval information directly on the FDA website.

This long clinical history and an established pharmaceutical safety profile are part of why researchers across many fields continue studying the molecule. It is a well-characterized compound with a known mechanism of action, which makes it a practical subject for scientific inquiry.

One important distinction: Nutricel sells methylene blue as a dietary supplement. That is a different regulatory category from a prescription drug. Dietary supplements are not FDA-approved drugs, are not intended to treat or prevent any disease, and are held to a different standard under federal law. The research described on this page was conducted in clinical, laboratory, or animal settings, not in the context of dietary supplementation.

How Methylene Blue Interacts with Cells

To understand why researchers are interested in methylene blue, it helps to understand a basic process that happens inside every cell in your body.

Cells produce energy inside small structures called mitochondria. Inside mitochondria, a series of protein complexes work together like a relay race, passing electrons from one complex to the next. That relay drives the production of ATP, the molecule your cells use as fuel. When the relay runs efficiently, cells have energy. When it slows down or breaks down, as often happens with aging, disease, or injury, energy production drops.

Methylene blue is capable of accepting and donating electrons. Researchers have found that it can slot into the electron transport chain as a kind of backup carrier, potentially helping the relay keep running even when some of the usual protein complexes are not functioning at full capacity.

Dr. Francisco Gonzalez-Lima at the University of Texas at Austin is widely regarded as the leading researcher in this area. His laboratory has published extensively on how methylene blue affects brain energy metabolism and cognitive function across multiple study types over several decades.

One important nuance from this research: methylene blue does not behave the same way at all doses. Lower doses tend to produce different results than higher doses, and at very high doses the relationship can reverse entirely. This is called a biphasic or dose-dependent response, meaning the dose matters enormously and effects do not simply scale upward in a straight line. This pattern is relevant to interpreting study results and to understanding why dosing in research varies so widely.

What the Research Shows

Memory and Learning

One frequently cited early study is Riha et al. (2005), published in the European Journal of Pharmacology. Researchers administered methylene blue to rodents at different doses and then tested the animals on spatial memory tasks, including maze navigation. They also measured oxygen consumption in brain tissue. The study found dose-dependent effects on both memory performance and oxygen use in brain regions involved in learning. Lower doses produced measurable differences from controls; higher doses did not show the same pattern. You can read the abstract at PubMed PMID 15763243. These were rodent models, and results from animal studies do not automatically transfer to humans.

A 2017 study published in Brain Imaging and Behavior examined healthy human volunteers using fMRI, a brain imaging technique that measures blood flow as a proxy for brain activity. Researchers found differences in functional connectivity (the degree to which different brain regions communicate with each other) in participants who received a low oral dose of methylene blue compared to those who received a placebo. The full study is available at PMC5018244. This was a small study in healthy adults, not a clinical trial in people with memory disorders.

Brain Energy and Blood Flow

A 2012 study published in PLOS One investigated how methylene blue affected the brain's use of oxygen, often described as the brain's metabolic rate. Researchers used brain imaging to measure the cerebral metabolic rate of oxygen, essentially how fast the brain is burning through its fuel supply. They found differences in regional brain metabolism in participants who received methylene blue compared to controls. The study is available at doi.org/10.1371/journal.pone.0046585. Changes in how the brain uses oxygen are relevant to research on aging and cognitive decline, though this study was not conducted in clinical patient populations.

Brain Recovery After Injury

A 2016 study published in the journal Neuroscience examined methylene blue in the context of stroke, using animal models. Researchers looked at neurogenesis, the process by which the brain produces new neurons (nerve cells), in regions affected by stroke. They reported that methylene blue treatment was associated with increased neurogenesis and improved recovery markers in the animals studied. You can find the abstract at ibroneuroscience.org. These findings were in animal models. Stroke research conducted in rodents has historically been difficult to replicate in human clinical trials, and this area remains under investigation.

Cellular Aging and Mitochondria

A separate thread of research looks at how mitochondrial function changes as cells age. As people get older, the electron transport chain in mitochondria tends to become less efficient. Cells produce less energy and accumulate more oxidative stress, a term for the chemical byproducts of metabolism that can damage cellular structures over time.

Because methylene blue can participate in electron transport, researchers have studied whether it might help offset some of this age-related decline in mitochondrial efficiency. Dr. Gonzalez-Lima's laboratory has contributed to this area, examining how the molecule affects brain cells under conditions that mimic age-related metabolic stress. This work is conducted primarily in cell cultures and animal models. Human aging studies are far more complex and have not yet produced definitive clinical conclusions.

Additional Areas Researchers Are Exploring

Skin Cell Aging

A 2017 study by Bhatt et al., published in Scientific Reports (a Nature Publishing Group journal), examined how methylene blue affected human skin fibroblasts. Fibroblasts are cells found in the skin that produce collagen and other structural proteins that give skin its firmness and elasticity. The researchers applied methylene blue to fibroblast cell cultures taken from donors of different ages and looked at markers associated with cellular aging, including mitochondrial function and signs of cellular senescence (a state where cells stop dividing normally).

They found that cells treated with methylene blue showed reduced markers of cellular aging and improved mitochondrial function compared to untreated cells. The study is available at nature.com/articles/s41598-017-05913-4. This was an in-vitro study conducted entirely in cell cultures in a laboratory setting, not in living humans. Results from cell culture experiments cannot be assumed to predict outcomes in people using a supplement or topical product.

Alzheimer's Disease Research

One of the hallmarks of Alzheimer's disease is the accumulation of tau protein inside brain cells. Tau normally helps stabilize cell structure, but in Alzheimer's it becomes chemically altered and clumps together into twisted tangles that interfere with cell function. Researchers have investigated whether certain compounds could prevent or disrupt these clumping events.

Methylene blue and a related compound called LMTM (leuco-methylthioninium) have been studied in this context. A 2016 clinical trial by Wischik and colleagues examined LMTM in patients with mild to moderate Alzheimer's disease. The results were mixed. The compound did not meet its primary endpoints in the full patient group. Some secondary analyses suggested possible benefit in patients not taking other Alzheimer's medications, but these findings were not conclusive and the compound has not received regulatory approval as an Alzheimer's treatment. You can read the trial summary at PubMed PMID 26756015. Research in this area is ongoing, and no methylene blue-based Alzheimer's drug has been approved.

Antimicrobial and Photodynamic Research

Methylene blue's antimicrobial properties have been recognized since the late 19th century, predating modern antibiotics by decades. More recently, researchers have studied a technique called photodynamic inactivation, in which methylene blue is applied to a surface or tissue and then activated by a specific wavelength of light. When activated this way, the molecule generates reactive compounds that can disrupt the outer membranes of bacteria and other microorganisms.

This approach has been studied in dental applications, including treating gum disease and decontaminating root canals, and in wound care for managing bacterial biofilms (layers of bacteria that form on surfaces and resist standard treatment). Some of these applications are used clinically in various countries. This research context is quite different from oral supplementation, where the molecule travels through the digestive system rather than being applied directly to a targeted site with light activation.

Why Most of This Research Does Not Directly Apply to Supplements

Reading research summaries can make it tempting to assume that the findings translate directly into benefits from taking a supplement. That assumption requires caution for several reasons.

First, many of the studies described above used intravenous delivery, direct application to cell cultures, or injection in animal models. Intravenous delivery bypasses the digestive system entirely and achieves different blood concentrations than an oral dose. What a molecule does when delivered directly into the bloodstream is not the same as what it does after passing through the stomach and intestines.

Second, effective doses vary dramatically across studies, and most human research has used tightly controlled doses in specific clinical populations under medical supervision. The relationship between dose and effect is not straightforward.

Third, cell culture studies show what a compound does to isolated cells in a dish. Living organisms are far more complex. Many compounds that show strong effects in cell cultures do not produce the same results in animals, and many animal study results do not replicate in humans.

This page presents what the research community has found. It does not suggest that taking methylene blue as a dietary supplement will produce any of these outcomes.

Read the Studies Yourself

The best way to evaluate scientific research is to read it directly. PubMed is a free database maintained by the National Institutes of Health that indexes peer-reviewed research from journals around the world. You can search for methylene blue studies, filter by study type, and access abstracts at no cost, with full text available for many articles.

Start your search at pubmed.ncbi.nlm.nih.gov.

These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.